

DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

Relevant Financial Relationships

The following individuals involved in the planning, development, review, presentation, authoring and/or editing of the symposium content have disclosed relevant financial relationships with ineligible companies*, and the CME Department has mitigated these potential conflicts of interest. **Indicates that this individual's presentation(s) will include discussion of off-label or unapproved usage.

- **Catherine Bollard, M.D.**, faculty for this educational activity is a consultant for SOBI, Galapagos and Minovia Therapeutics and an advisor for Catamaran Bio. She also has an executive role with Cabaletta Bio, part ownership with Mana Therapeutics and individual stocks/stock options with Neximmune and Repertoire Immune Medicine. She has indicated that the presentation or discussion will* include off-label or unapproved product usage.
- **Adam Cohen, M.D.**, faculty for this educational activity, is a researcher for Novartis, Janssen, GSK and Genentech; a consultant for GSK, BMS/Celgene, Genentech/Roche, Janssen, Oncocept, Pfizer, AbbVie, Arcellx, Takeda, AstraZeneca and Ichnos and has an executive role with Novartis. He has indicated that the presentation or discussion will* include off-label or unapproved product usage.
- **Charles Dimitroff, Ph.D.**, faculty for this educational activity, has no relevant financial relationships with ineligible companies to disclose and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Patricio Duarte, M.D.**, faculty for this educational activity is a researcher for Sanofi, BMS and Janssen; an advisor for Sanofi and Janssen; and a member of the speakers bureau for Sanofi, Janssen and BMS. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Aleksandra Filipovic, M.D.**, faculty for this educational activity is an employee of PureTech Health and an advisor with Sharing Progress in Cancer Care. She has indicated that the presentation or discussion will* include off-label or unapproved product usage.
- **Leo Luznik, M.D.**, faculty for this educational activity is a researcher for Merck and Genentech; an advisor for Gilead Sciences, Rubius Therapeutics, Precision Biosciences, Talaris Therapeutics and Johnson & Johnson. He has a patent WindMIL Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Matthew Matasar, M.D.**, faculty for this educational activity is a researcher with Bayer, Immunovaccine Technologies, Janssen, Genentech, GM Biosciences, Pharmacocyclics, Roche and Seattle Genetics; a consultant with Bayer, Juno Therapeutics, Genentech, Roche, Seattle Genetics, Takeda and Teva; and an advisor for Genentech and Merck. He has part ownership in Merck and has received support from ADC Therapeutics, AstraZeneca, BMS, Celgene, Epizyme, IMV Therapeutics, Kite, Regeneron and Seagen. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Marcelo Pasquini, M.D.**, faculty for this educational activity is a researcher for BMS, Kite, Janssen and Novartis; a consultant with BMS; and a member of the speaker's bureau for Gilead Brazil. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Rajit Rampal, M.D.**, faculty for this educational activity, is a researcher with Incyte, Celgene/BMS, Blueprint, AbbVie, CTI, Stemline, Galeco, PharmaEssentia, Jubilant, Constellation/Morphosys, Sierra Oncology/GSK, Protagonist, Cogent, Summitomo Daiippon, Kartos, Servier, Zentaris and Karyopharm. He is an independent research contractor with Constellation Pharmaceuticals, Ryvu, Zentaris and Stemline Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Paul Richardson, M.D.**, faculty for this educational activity, is a researcher with Oncocept, Celgene/BMS, Karyopharm, Sanofi and GSK, and a consultant with Oncocept, Celgene/BMS, Karyopharm, Sanofi, GSK, Regeneron and Takeda. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Michel Sadelain, M.D., Ph.D.**, faculty for this educational activity, is a researcher with Atara Biotherapeutics, Mnemo Therapeutics, Takeda and Fate Biotherapeutics. He holds royalties with Fate Biotherapeutics and has stocks with Mnemo Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Craig Sauter, M.D.**, faculty for this educational activity is a consultant with Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme, Cargo Therapeutics, Affimed and NKARTA. He is an advisor with Kite/Gilead, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

- **David A. Scheinberg, M.D.**, faculty for this educational activity is a researcher with Coimmune and Eureka. He is an advisor with Eureka, Actinium, Repertoire, Oncoprep, Pfizer, Sellas and Sapience. He receives royalties from Sellas, Actinium, Coimmune and Clade. He has part ownership of Sellas, Actinium, Pfizer, Sapience, Eureka and ISRG. He has indicated that the presentation will* include off-label or unapproved product usage.
- **Robert Soiffer, M.D.**, faculty for this educational activity is a consultant with Astellas, Amgen, Vor Biopharma, Smart Immune, Neovii, Bluesphere Bio and Jasper. He is on the board of directors for NMPD. He has indicated that the presentation and discussion will not include off-label or unapproved product usage.
- **Eytan Stein, M.D.**, faculty for this educational activity is a researcher with Novartis, Janssen, BMS, Agios, Jazz, Menarini, Genentech, Genesis, AbbVie, Neoleukin, Gilead, Syndax, OnCusp, CTI Biopharma, Foghorn, Servier, Calithera, Daiichi, Aptose, Syros, Astellas, Ono Pharma and Blueprint. He receives honorariums from Kura; is part of safety monitoring for Epizyme and Collectis and has received research funding from Eisai and BMS. He has indicated that the presentation or discussion will* include off-label or unapproved product usage.
- **Wendy Stock, M.D.**, faculty for this educational activity, is a researcher with Kura and Newave. She is a consultant for Servier and Newave. She has indicated that the presentation or discussion will* include off-label or unapproved product usage.
- **Richard Stone, M.D.**, faculty for this educational activity, is a consultant for AbbVie, Amgen, AvenCell, BerGen Bio, BMS, Cellularity, CTI Biopharma, Curis Oncology, Daiichi Sankyo, GSK, Hermavant, Jazz, Kura Oncology, Ligand Pharma, Lava Therapeutics, Redona Therapeutics and Rigel Therapeutics. He has received honorariums for DSMB's from Aptevo, Epizyme, Syntrix and Takeda. He has indicated that the presentation or discussion will* include off-label or unapproved product usage.
- **Saad Usmani, M.D.**, faculty for this educational activity is a researcher for AbbVie, Amgen, Array Biopharma, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GSK, Janssen, Merck, Moderna, Pharmacyclics, Sanofi, Seagen, Skyline Dx, Takeda and TeneoBio. He is a consultant for AbbVie, Amgen, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GSK, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura Bio, SkylineDx and Takeda. He is an advisor for AbbVie, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GSK, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura Bio, SkylineDx and Takeda. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.
- **Marcel van den Brink, M.D., Ph.D.**, faculty for this educational activity is a researcher for Seres Therapeutics; a consultant for Merck, Magenta Therapeutics, WindMIL Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Priothera, Ceramedix, Lyngogenesis, Pluto Therapeutics and Da Volterra and an advisor for Rheos and GSK. He receives royalties from Wolters Kluwer; has an executive role with DKMS; and has stocks in Seres Therapeutics, Notch Therapeutics and Pluto Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Nothing to Disclose

- **Guenther Koehne, M.D.**, director for this activity, has indicated that he has no relevant financial relationships with ineligible companies to disclose, and has indicated that the presentation and discussion will not include off-label or unapproved product usage.
- **Stacey Berrios, P.A.-C.**, content reviewer for this activity, has indicated that she has no relevant financial relationships with ineligible companies to disclose.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships with ineligible companies to disclose.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*